GlassScriptPhysician profile
Ju Dong Yang
NPI 1982854311
$45,646.05
in general payments reported to CMS, 2019-2025
14 companies · $8,400 in 2025
The $8,400 reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $6,496 · 2021: $5,100 · 2022: $9,283 · 2023: $13K · 2024: $2,875 · 2025: $8,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,242 · Travel and Lodging: $1,370 · Food and Beverage: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,743.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,241.86 |
| Travel and Lodging | $1,370.26 |
| Food and Beverage | $1,219.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $14,590.41 | 2020-2025 | |
| Fujifilm Healthcare Americas Corporation | $10,879.11 | 2020-2025 | Utaswako Afp-L3 |
| Exact Sciences Corporation | $6,406.61 | 2023-2025 | Cologuard Collection Kit |
| Exelixis INC. | $5,267.64 | 2019-2022 | |
| Gilead Sciences, INC. | $4,404.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,383.78 | 2022 | |
| Merck Sharp & Dohme LLC | $1,220.00 | 2023 | |
| Madrigal Pharmaceuticals | $187.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion, INC. | $150.00 | 2025 | |
| Genentech, INC. | $86.98 | 2025 | Tecentriq |
| Novo Nordisk INC | $47.30 | 2024 | |
| Abbvie INC. | $22.40 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ju Dong Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.